Molecular modeling studies, synthesis and biological evaluation of derivatives of N-phenylbenzamide as Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors

Medicinal Chemistry Research

Volumn 20, Issue 3, 2011, Pages 321-332

  Desai, Kumar R ^a   Shaikh, Mushtaque S ^a   Coutinho, Evans C ^a  

^a BOMBAY COLLEGE OF PHARMACY   (India)

Author keywords

3D QSAR; Antimalarials; Docking; N Phenylbenzamide; PfDHODH

Indexed keywords

ANTIMALARIAL AGENT; ARTESUNATE; BENZAMIDE DERIVATIVE; CHLOROQUINE; DIHYDROOROTATE DEHYDROGENASE INHIBITOR;

ANTIMALARIAL ACTIVITY; ARTICLE; CELL ASSAY; CONTROLLED STUDY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; MOLECULAR DOCKING; MOLECULAR MODEL; NONHUMAN; PLASMODIUM FALCIPARUM; SPECTROSCOPY;

EID: 79958096498     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-010-9323-4     Document Type: Article

References (38)

1. Baldwin J, Farajallah AM, Malmquist NA, Rathod PK, Phillips MA (2002) Malarial dihydroorotate dehydrogenase. Substrate and inhibitor specificity. J Biol Chem 277:41827. doi:10.1074/jbc.M206854200
2. Baldwin J, Michnoff CH, Malmquist NA, White J, Roth MG, Rathod PK, Phillips MA (2005) High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. J Biol Chem 280:21847. doi:10.1074/jbc.M501100200
3. Baumann P, Mandl-Weber S, Volkl A, Adam C, Bumeder I, Oduncu F, Schmidmaier R (2009) Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. Mol Cancer Ther 8:366. doi:10.1158/1535-7163.MCT-08-0664
4. Becker K, Kirk K (2004) Of malaria, metabolism and membrane transport. TRENDS Parasitol 20:590. doi:10.1016/j.pt.2004.09.004
5. Boa AN, Canavan SP, Hirst PR, Ramsey C, Stead AM, McConkey GA (2005) Synthesis of brequinar analogue inhibitors of malaria parasite dihydroorotate dehydrogenase. Bioorg Med Chem 13:1945. doi:10.1016/j.bmc.2005.01.017
6. Breman JG (2001) The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. Am J Trop Med Hyg 64:1
7. Bush BL, Nachbar RB Jr (1993) Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA. J Comput Aided Mol Des 7:587
8. Chiang PK, Bujnicki JM, Su X, Lanar DE (2006) Malaria: therapy, genes and vaccines. Curr Mol Med 6:309
9. Cramer RD, Patterson DE, Bunce JD (1988) Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110:5959. doi:10.1021/ja00226a005
10. Cramer RD III, Patterson DE, Bunce JD (1989) Recent advances in comparative molecular field analysis (CoMFA). Prog Clin Biol Res 291:161
11. Davis JP, Cain GA, Pitts WJ, Magolda RL, Copeland RA (1996) The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 35:1270. doi:10.1021/bi952168g
12. Elkayam O, Yaron I, Shirazi I, Judovitch R, Caspi D, Yaron M (2003) Active leflunomide metabolite inhibits interleukin 1beta, tumour necrosis factor alpha, nitric oxide, and metalloproteinase-3 production in activated human synovial tissue cultures. Ann Rheum Dis 62:440
13. Fidock DA, Rosenthal PJ, Croft SL, Brun R, Nwaka S (2004) Antimalarial drug discovery: efficacy models for compound screening. Nat Rev Drug Discov 3:509. doi:10.1038/nrd1416
14. Freundlich JS, Yu M, Lucumi E, Kuo M, Tsai HC, Valderramos JC, Karagyozov L, Jacobs WR Jr, Schiehser GA, Fidock DA, Jacobus DP, Sacchettini JC (2006) Synthesis and biological activity of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 2: 20-substituted triclosan derivatives. Bioorg Med Chem Lett 16:2163. doi:10.1016/j.bmcl.2006.01.051
15. Gramatica P (2007) Principles of QSAR models validation: internal and external. QSAR Comb Sci 26:694
16. Gujjar R, Marwaha A, El Mazouni F, White J, White KL, Creason S, Shackleford DM, Baldwin J, Charman WN, Buckner FS, Charman S, Rathod PK, Phillips MA (2009) Identification of a metabolically stable triazolopyrimidine- based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice. J Med Chem 52:1864. doi:10.1021/jm801343r
17. Hamilton LC, Vojnovic I, Warner TD (1999) A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclooxygenase-2 in vitro and in vivo in a substrate-sensitive manner. Br J Pharmacol 127:1589. doi:10.1038/sj.bjp.0702708
18. Heikkila T, Thirumalairajan S, Davies M, Parsons MR, McConkey AG, Fishwick CW, Johnson AP (2006) The first de novo designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. Bioorg Med Chem Lett 16:88. doi:10.1016/j.bmcl.2005.09.045
19. Heikkila T, Ramsey C, Davies M, Galtier C, Stead AM, Johnson AP, Fishwick CW, Boa AN, McConkey GA (2007) Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase. J Med Chem 50:186. doi:10.1021/jm060687j
20. Hurt DE, Widom J, Clardy J (2006) Structure of Plasmodium falciparum dihydroorotate dehydrogenase with a bound inhibitor. Acta Crystallogr D 62:312. doi:10.1107/S0907444905042642
21. Kalra BS, Chawla S, Gupta P, Valecha N (2006) Screening of antimalarial drugs: an overview. Indian J Pharmacol 38:5
22. Klebe G (1998) Comparative molecular similarity indices analysis: CoMSIA. Perspect Drug Discov Des 12:87. doi:10.1023/A:1017025803403
23. Klebe G, Abraham U, Mietzner T (1994) Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 37:4130
24. Kobayashi Y, Ueyama S, Arai Y, Yoshida Y, Kaneda T, Sato T, Shin K, Kumegawa M, Hakeda Y (2004) The active metabolite of leflunomide, A771726, inhibits both the generation of and the bone-resorbing activity of osteoclasts by acting directly on cells of the osteoclast lineage. J Bone Miner Metab 22:318. doi:10.1007/s00774-003-0489-4
25. Li WD, Lin ZB (2002) Effects of leflunomide and its active metabolite on the production and mRNA expression of TNF-alpha in peritoneal macrophages and synovial cells with adjuvant arthritis in rats. Yao Xue Xue Bao 37:767
26. McRobert L, McConkey GA (2002) RNA interference (RNAi) inhibits growth of Plasmodium falciparum. Mol Biochem Parasitol 119:273. doi: S0166685101004297[pii]
27. Otsuka T, Koyama T, Ohtani R, Niiro H, Yoshizawa S, Harada M, Inokuma S (2008) Leflunomide-induced lung injury that developed after its withdrawal, coinciding with peripheral blood lymphocyte count decrease. Mod Rheumatol 18:96. doi:10.1007/s10165-007-0014-z
28. Perreux L, Loupy A, Delmotte M (2003) Microwave effects in solvent-free esters aminolysis. Tetrahedron 59:2185. doi:10.1016/S0040-4020(03)00151-0
29. Phillips MA, Gujjar R, Malmquist NA, White J, El Mazouni F, Baldwin J, Rathod PK (2008) Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falciparum. J Med Chem 51:3649. doi:10.1021/jm8001026
30. Quashie NB, de Koning HP, Ranford-Cartwright LC (2006) An improved and highly sensitive microfluorimetric method for assessing susceptibility of Plasmodium falciparum to antimalarial drugs in vitro. Malar J 5:95. doi:10.1186/1475-2875-5-95
31. Richard D, Cramer RD III, Bunce JD, Patterson DE, Frank IE (1988) Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies. Quant. Struct. Act. Relat. 7:18
32. Ridley RG (2002) Medical need, scientific opportunity and the drive for antimalarial drugs. Nature 415:686. doi:10.1038/415686a
33. Shao J (1996) Bootstrap model selection. J Am Stat Assoc 91:655
34. Wold S, Johansson E, Cocchi M (1993) In: Kubinyi H (ed) 3D QSAR in drug design: theory, methods and applications. ESCOM Science Publishers, Leiden, p 523
35. Yao HW, Li J, Chen JQ, Xu SY (2004a) A 771726, the active metabolite of leflunomide, inhibits TNF-alpha and IL-1 from Kupffer cells. Inflammation 28:97
36. Yao HW, Li J, Chen JQ, Xu SY (2004b) The active metabolite of leflunomide A771726 inhibits proliferation and collagen synthesis of hepatic stellate cell. Zhejiang Xue Xue Bao Yi Xue Ban 33:515
37. Zhang X, Zhou H, Dong GF, Shi YZ (2005) An exploratory study on in vitro effects and mechanism of leflunomide on dendritic cells of systemic lupus erythematosus. Zhonghua Nei Ke Za Zhi 44:370
38. Zhang M, Hao N, Bian F (2008) The active metabolite of leflunomide A771726 inhibits corneal neovascularization. J Huazhong Univ Sci Technol Med Sci 28:364. doi:10.1007/s11596-008-0332-1